![glp-1 and hs Translated article] Glucagon-Like Peptide-1 Agonists for Treating Obesity in Patients With Immune-Mediated Skin Diseases Current Insights, Advantages and Challenges](https://ars.els-cdn.com/content/image/1-s2.0-S0001731023008505-fx1.jpg)
glp-1 and hs
Shipping Estimate
glp-1 and hs Translated article] Glucagon-Like Peptide-1 Agonists for Treating Obesity in Patients With Immune-Mediated Skin Diseases Current Insights, Advantages and Challenges
USD27.74
USD76.74
Pay in 4 interest-free payments of $6.93 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Oct 18 - Oct 23
![glp-1 and hs Translated article] Glucagon-Like Peptide-1 Agonists for Treating Obesity in Patients With Immune-Mediated Skin Diseases Current Insights, Advantages and Challenges](https://s3.amazonaws.com/production.scholastica/public/attachments/bd59d6e4-c76b-4a0f-853f-f18e54c05fbd/small/figure_2._principal_mechanisms_lead_by_glp-1r_activation.png)
![glp-1 and hs Translated article] Glucagon-Like Peptide-1 Agonists for Treating Obesity in Patients With Immune-Mediated Skin Diseases Current Insights, Advantages and Challenges](https://ars.els-cdn.com/content/image/1-s2.0-S1043661822002651-ga1.jpg)
![glp-1 and hs Translated article] Glucagon-Like Peptide-1 Agonists for Treating Obesity in Patients With Immune-Mediated Skin Diseases Current Insights, Advantages and Challenges](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b0d/11547001/7055e72d304a/jcm-13-06292-g003.jpg)
![glp-1 and hs Translated article] Glucagon-Like Peptide-1 Agonists for Treating Obesity in Patients With Immune-Mediated Skin Diseases Current Insights, Advantages and Challenges](https://assets.medpagetoday.net/media/images/122xxx/122005.jpg?width=0.8)
![glp-1 and hs Translated article] Glucagon-Like Peptide-1 Agonists for Treating Obesity in Patients With Immune-Mediated Skin Diseases Current Insights, Advantages and Challenges](https://blogs.cornell.edu/communityeducation/files/2025/09/GLP-830x581.jpg)
![glp-1 and hs Translated article] Glucagon-Like Peptide-1 Agonists for Treating Obesity in Patients With Immune-Mediated Skin Diseases Current Insights, Advantages and Challenges](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13098-025-01623-w/MediaObjects/13098_2025_1623_Fig2_HTML.png)
